ENROLLED
2025
Legislature
CS for CS for SB 1768, 1st Engrossed
First Engrossed
20251768e120251768er
1 A bill to be entitled
1
2 An act relating to stem cell therapy; creating ss.
709 párrafos sin cambios
3 458.3245 and 459.0127, F.S.; providing legislative
4 findings and intent; defining terms; authorizing
5 physicians to perform stem cell therapy not approved
6 by the United States Food and Drug Administration
7 under certain circumstances; specifying requirements
8 for the stem cells that may be used by such
9 physicians; requiring such physicians to adhere to
10 applicable current good manufacturing practices in the
11 performance of such therapies; requiring physicians to
12 include a specified notice in any form of
13 advertisement; providing requirements for such notice;
14 requiring physicians to obtain a signed consent form
15 from the patient or his or her representative before
16 performing the therapy; specifying requirements for
17 the consent form; providing applicability; providing
18 for disciplinary action; providing criminal penalties;
19 authorizing the Board of Medicine to adopt rules;
20 providing an effective date.
21
22 Be It Enacted by the Legislature of the State of Florida:
23
24 Section 1. Section 458.3245, Florida Statutes, is created
25 to read:
26
458.3245 Stem cell therapy.—
27
(1) The Legislature recognizes the significant potential of
28
stem cell therapies in advancing medical treatments and
29
improving patient outcomes and further recognizes the need to
30
ensure that such therapies are provided using stem cells
31
obtained in an ethical manner that does not involve stem cells
32
derived from aborted fetuses. It is the intent of the
33
Legislature to foster medical innovation while upholding ethical
34
standards that respect the sanctity of life. By encouraging the
35
use of stem cell sources such as adult stem cells, umbilical
36
cord blood, and other ethically obtained human cells, tissues,
37
or cellular or tissue-based products, the state will advance
38
regenerative medicine in a manner consistent with the values of
39
this state.
40
(2) As used in this section, the term:
41
(a) “Human cells, tissues, or cellular or tissue-based
42
products” means articles containing or consisting of human cells
43
or tissues that are intended for implantation, transplantation,
44
infusion, or transfer into a human recipient. The term does not
45
include:
46
1. Vascularized human organs for transplantation;
47
2. Whole blood or blood components or blood derivative
48
products;
49
3. Secreted or extracted human products, such as milk,
50
collagen, and cell factors, other than semen;
51
4. Minimally manipulated bone marrow for homologous use and
52
not combined with another article other than water,
53
crystalloids, or a sterilizing, preserving, or storage agent, if
54
the addition of the agent does not raise new clinical safety
55
concerns with respect to the bone marrow;
56
5. Ancillary products used in the manufacture of human
57
cells, tissues, or cellular or tissue-based products;
58
6. Cells, tissues, and organs derived from animals other
59
than humans;
60
7. In vitro diagnostic products; or
61
8. Blood vessels recovered with an organ which are intended
62
for use in organ transplantation and labeled “For use in organ
63
transplantation only.”
64
(b) “Minimally manipulated” means:
65
1. For structural tissue, processing that does not alter
66
the original relevant characteristics of the tissue relating to
67
the tissue’s utility for reconstruction, repair, or replacement.
68
2. For cells or nonstructural tissues, processing that does
69
not alter the relevant biological characteristics of cells or
70
tissues.
71
(c) “Physician” means a physician licensed under this
72
chapter acting in the course and scope of his or her employment.
73
(d) “Stem cell therapy” means a treatment involving the use
74
of afterbirth placental perinatal stem cells, or human cells,
75
tissues, or cellular or tissue-based products, which complies
76
with the regulatory requirements provided in this section. The
77
term does not include treatment or research using human cells or
78
tissues that were derived from a fetus or an embryo after an
79
abortion.
80
(3)(a) A physician may perform stem cell therapy that is
81
not approved by the United States Food and Drug Administration
82
if such therapy is used for treatment or procedures that are
83
within the scope of practice for such physician and the
84
therapies are related to orthopedics, wound care, or pain
85
management.
86
(b) To ensure that the retrieval, manufacture, storage, and
87
use of stem cells used for therapies conducted under this
88
section meet the highest standards, any stem cells used by a
89
physician for therapy provided under this section must:
90
1. Be retrieved, manufactured, and stored in a facility
91
that is registered and regulated by the United States Food and
92
Drug Administration;
93
2. Be retrieved, manufactured, and stored in a facility
94
that is certified or accredited by one of the following
95
entities:
96
a. National Marrow Donor Program.
97
b. World Marrow Donor Association.
98
c. Association for the Advancement of Blood and
99
Biotherapies.
100
d. American Association of Tissue Banks; and
101
3. Contain viable or live cells upon post-thaw analysis and
102
be included in a post-thaw viability analysis report for the
103
product lot which will be sent to the physician before use with
104
the physician’s patient.
105
(c) A physician performing stem cell therapy may not obtain
106
stem cells for therapies from a facility engaging in the
107
retrieval, manufacture, or storage of stem cells intended for
108
human use under this section unless the facility maintains valid
109
certification or accreditation as required by this subsection.
110
Any contract or other agreement by which a physician obtains
111
stem cells for therapies from such a facility must include the
112
following:
113
1. A requirement that the facility provide all of the
114
following information to the physician:
115
a. The name and address of the facility.
116
b. The certifying or accrediting organization.
117
c. The type and scope of certification or accreditation.
118
d. The effective and expiration dates of the certification
119
or accreditation.
120
e. Any limitations or conditions imposed by the certifying
121
or accrediting organization.
122
2. A requirement that the facility notify the physician
123
within 30 days after any change in certification or
124
accreditation status, including renewal, suspension, revocation,
125
or expiration.
126
(4) In the performance of any procedure using or purporting
127
to use stem cells or products containing stem cells, the
128
physician shall use stem cell therapy products obtained from
129
facilities that adhere to the applicable current good
130
manufacturing practices for the collection, removal, processing,
131
implantation, and transfer of stem cells, or products containing
132
stem cells, pursuant to the Federal Food, Drug, and Cosmetic
133
Act, 21 U.S.C. ss. 301 et seq.; 52 Stat. 1040 et seq.; and 21
134
C.F.R. part 1271, Human Cells, Tissues, and Cellular and Tissue
135
Based Products.
136
(5)(a) A physician who conducts stem cell therapy pursuant
137
to this section shall include the following in any form of
138
advertisement:
139
140
THIS NOTICE MUST BE PROVIDED TO YOU UNDER FLORIDA LAW.
141
This physician performs one or more stem cell
142
therapies that have not yet been approved by the
143
United States Food and Drug Administration. You are
144
encouraged to consult with your primary care provider
145
before undergoing any stem cell therapy.
146
147
(b) The notice required under paragraph (a) must be clearly
148
legible and in a type size no smaller than the largest type size
149
used in the advertisement.
150
(6)(a) A physician who conducts stem cell therapy pursuant
151
to this section shall obtain a signed consent form from the
152
patient before performing the stem cell therapy.
153
(b) The consent form must be signed by the patient or, if
154
the patient is not legally competent, the patient’s
155
representative and must state all of the following in language
156
the patient or his or her representative may reasonably be
157
expected to understand:
158
1. The nature and character of the proposed treatment.
159
2. That the proposed stem cell therapy has not yet been
160
approved by the United States Food and Drug Administration.
161
3. The anticipated results of the proposed treatment.
162
4. The recognized serious possible risks, complications,
163
and anticipated benefits involved in the treatment and in the
164
recognized possible alternative forms of treatment, including
165
nontreatment.
166
5. That the patient is encouraged to consult with his or
167
her primary care provider before undergoing any stem cell
168
therapy.
169
(7) This section does not apply to the following:
170
(a) A physician who has obtained approval for an
171
investigational new drug or device from the United States Food
172
and Drug Administration for the use of human cells, tissues, or
173
cellular or tissue-based products; or
174
(b) A physician who performs stem cell therapy under an
175
employment or other contract on behalf of an institution
176
certified or accredited by any of the following:
177
1. The Foundation for the Accreditation of Cellular
178
Therapy.
179
2. The Blood and Marrow Transplant Clinical Trials Network.
180
3. The Association for the Advancement of Blood and
181
Biotherapies.
182
4. An entity with expertise in stem cell therapy as
183
determined by the department.
184
(8) A violation of this section may subject the physician
185
to disciplinary action by the board.
186
(9) A physician who willfully performs, or actively
187
participates in, the following commits a felony of the third
188
degree, punishable as provided in s. 775.082, s. 775.083, or s.
189
775.084, and is subject to disciplinary action under this
190
chapter and s. 456.072:
191
(a) Treatment or research using human cells or tissues
192
derived from a fetus or an embryo after an abortion; or
193
(b) The sale, manufacture, or distribution of computer
194
products created using human cells, tissues, or cellular or
195
tissue-based products.
196
(10) The board may adopt rules necessary to implement this
197
section.
198 Section 2. Section 459.0127, Florida Statutes, is created
199 to read:
200
459.0127 Stem cell therapy.—
201
(1) The Legislature recognizes the significant potential of
202
stem cell therapies in advancing medical treatments and
203
improving patient outcomes and further recognizes the need to
204
ensure that such therapies are provided using stem cells
205
obtained in an ethical manner that does not involve stem cells
206
derived from aborted fetuses. It is the intent of the
207
Legislature to foster medical innovation while upholding ethical
208
standards that respect the sanctity of life. By encouraging the
209
use of stem cell sources such as adult stem cells, umbilical
210
cord blood, and other ethically obtained human cells, tissues,
211
or cellular or tissue-based products, the state will advance
212
regenerative medicine in a manner consistent with the values of
213
this state.
214
(2) As used in this section, the term:
215
(a) “Human cells, tissues, or cellular or tissue-based
216
products” means articles containing or consisting of human cells
217
or tissues that are intended for implantation, transplantation,
218
infusion, or transfer into a human recipient. The term does not
219
include:
220
1. Vascularized human organs for transplantation;
221
2. Whole blood or blood components or blood derivative
222
products;
223
3. Secreted or extracted human products, such as milk,
224
collagen, and cell factors, other than semen;
225
4. Minimally manipulated bone marrow for homologous use and
226
not combined with another article other than water,
227
crystalloids, or a sterilizing, preserving, or storage agent, if
228
the addition of the agent does not raise new clinical safety
229
concerns with respect to the bone marrow;
230
5. Ancillary products used in the manufacture of human
231
cells, tissues, or cellular or tissue-based products;
232
6. Cells, tissues, and organs derived from animals other
233
than humans;
234
7. In vitro diagnostic products; or
235
8. Blood vessels recovered with an organ which are intended
236
for use in organ transplantation and labeled “For use in organ
237
transplantation only.”
238
(b) “Minimally manipulated” means:
239
1. For structural tissue, processing that does not alter
240
the original relevant characteristics of the tissue relating to
241
the tissue’s utility for reconstruction, repair, or replacement.
242
2. For cells or nonstructural tissues, processing that does
243
not alter the relevant biological characteristics of cells or
244
tissues.
245
(c) “Physician” means a physician licensed under this
246
chapter acting in the course and scope of his or her employment.
247
(d) “Stem cell therapy” means a treatment involving the use
248
of afterbirth placental perinatal stem cells, or human cells,
249
tissues, or cellular or tissue-based products, which complies
250
with the regulatory requirements provided in this section. The
251
term does not include treatment or research using human cells or
252
tissues that were derived from a fetus or an embryo after an
253
abortion.
254
(3)(a) A physician may perform stem cell therapy that is
255
not approved by the United States Food and Drug Administration
256
if such therapy is used for treatment or procedures that are
257
within the scope of practice for such physician and the
258
therapies are related to orthopedics, wound care, or pain
259
management.
260
(b) To ensure that the retrieval, manufacture, storage, and
261
use of stem cells used for therapies conducted under this
262
section meet the highest standards, any stem cells used by a
263
physician for therapy provided under this section must:
264
1. Be retrieved, manufactured, and stored in a facility
265
that is registered and regulated by the United States Food and
266
Drug Administration;
267
2. Be retrieved, manufactured, and stored in a facility
268
that is certified or accredited by one of the following
269
entities:
270
a. National Marrow Donor Program.
271
b. World Marrow Donor Association.
272
c. Association for the Advancement of Blood and
273
Biotherapies.
274
d. American Association of Tissue Banks; and
275
3. Contain viable or live cells upon post-thaw analysis and
276
be included in a post-thaw viability analysis report for the
277
product lot which will be sent to the physician before use with
278
the physician’s patient.
279
(c) A physician performing stem cell therapy may not obtain
280
stem cells for therapies from a facility engaging in the
281
retrieval, manufacture, or storage of stem cells intended for
282
human use under this section unless the facility maintains valid
283
certification or accreditation as required by this subsection.
284
Any contract or other agreement by which a physician obtains
285
stem cells for therapies from such a facility must include the
286
following:
287
1. A requirement that the facility provide all of the
288
following information to the physician:
289
a. The name and address of the facility.
290
b. The certifying or accrediting organization.
291
c. The type and scope of certification or accreditation.
292
d. The effective and expiration dates of the certification
293
or accreditation.
294
e. Any limitations or conditions imposed by the certifying
295
or accrediting organization.
296
2. A requirement that the facility notify the physician
297
within 30 days after any change in certification or
298
accreditation status, including renewal, suspension, revocation,
299
or expiration.
300
(4) In the performance of any procedure using or purporting
301
to use stem cells or products containing stem cells, the
302
physician shall use stem cell therapy products obtained from
303
facilities that adhere to the applicable current good
304
manufacturing practices for the collection, removal, processing,
305
implantation, and transfer of stem cells, or products containing
306
stem cells, pursuant to the Federal Food, Drug, and Cosmetic
307
Act, 21 U.S.C. ss. 301 et seq.; 52 Stat. 1040 et seq.; and 21
308
C.F.R. part 1271, Human Cells, Tissues, and Cellular and Tissue
309
Based Products.
310
(5)(a) A physician who conducts stem cell therapy pursuant
311
to this section shall include the following in any form of
312
advertisement:
313
314
THIS NOTICE MUST BE PROVIDED TO YOU UNDER FLORIDA LAW.
315
This physician performs one or more stem cell
316
therapies that have not yet been approved by the
317
United States Food and Drug Administration. You are
318
encouraged to consult with your primary care provider
319
before undergoing any stem cell therapy.
320
321
(b) The notice required under paragraph (a) must be clearly
322
legible and in a type size no smaller than the largest type size
323
used in the advertisement.
324
(6)(a) A physician who conducts stem cell therapy pursuant
325
to this section shall obtain a signed consent form from the
326
patient before performing the stem cell therapy.
327
(b) The consent form must be signed by the patient or, if
328
the patient is not legally competent, the patient’s
329
representative and must state all of the following in language
330
the patient or his or her representative may reasonably be
331
expected to understand:
332
1. The nature and character of the proposed treatment.
333
2. That the proposed stem cell therapy has not yet been
334
approved by the United States Food and Drug Administration.
335
3. The anticipated results of the proposed treatment.
336
4. The recognized serious possible risks, complications,
337
and anticipated benefits involved in the treatment and in the
338
recognized possible alternative forms of treatment, including
339
nontreatment.
340
5. That the patient is encouraged to consult with his or
341
her primary care provider before undergoing any stem cell
342
therapy.
343
(7) This section does not apply to the following:
344
(a) A physician who has obtained approval for an
345
investigational new drug or device from the United States Food
346
and Drug Administration for the use of human cells, tissues, or
347
cellular or tissue-based products; or
348
(b) A physician who performs stem cell therapy under an
349
employment or other contract on behalf of an institution
350
certified or accredited by any of the following:
351
1. The Foundation for the Accreditation of Cellular
352
Therapy.
353
2. The Blood and Marrow Transplant Clinical Trials Network.
354
3. The Association for the Advancement of Blood and
355
Biotherapies.
356
4. An entity with expertise in stem cell therapy as
357
determined by the department.
358
(8) A violation of this section may subject the physician
359
to disciplinary action by the board.
360
(9) A physician who willfully performs, or actively
361
participates in, the following commits a felony of the third
362
degree, punishable as provided in s. 775.082, s. 775.083, or s.
363
775.084, and is subject to disciplinary action under this
364
chapter and s. 456.072:
365
(a) Treatment or research using human cells or tissues
366
derived from a fetus or an embryo after an abortion; or
367
(b) The sale, manufacture, or distribution of computer
368
products created using human cells, tissues, or cellular or
369
tissue-based products.
370
(10) The board may adopt rules necessary to implement this
371
section.
372 Section 3. This act shall take effect July 1, 2025.